
Claire Chaussade

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12199461/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel pyrazolo[1,5- a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 187-190.	2.2	9
2	Vps34 Pl 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nature Communications, 2017, 8, 1804.	12.8	59
3	Inactivation of class II PI3K-C2α induces leptin resistance, age-dependent insulin resistance and obesity in male mice. Diabetologia, 2016, 59, 1503-1512.	6.3	23
4	Essential role of class II PI3K-C2α in platelet membrane morphology. Blood, 2015, 126, 1128-1137.	1.4	52
5	Inactivation of the Class II PI3K-C2β Potentiates Insulin Signaling and Sensitivity. Cell Reports, 2015, 13, 1881-1894.	6.4	66
6	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. MedChemComm, 2014, 5, 41-46.	3.4	12
7	Discovery of pyrazolo[1,5-a]pyridines as p110î±-selective PI3 kinase inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 69-85.	3.0	30
8	Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. Bioorganic and Medicinal Chemistry, 2012, 20, 58-68.	3.0	34
9	Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16217-16222.	7.1	36
10	Evidence for a role for the p110-α isoform of PI3K in skeletal function. Biochemical and Biophysical Research Communications, 2010, 391, 564-569.	2.1	11
11	Phosphoinositide-3-kinase (PI3K) inhibitors: Identification of new scaffolds using virtual screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5842-5847.	2.2	27
12	Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation. Biochemical and Biophysical Research Communications, 2009, 379, 830-834.	2.1	15
13	Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochemical and Biophysical Research Communications, 2009, 381, 577-581.	2.1	50
14	Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochemical Journal, 2007, 404, 449-458.	3.7	188
15	Nuclear Forkhead Box O1 Controls and Integrates Key Signaling Pathways in Hepatocytes. Endocrinology, 2007, 148, 2424-2434.	2.8	39
16	Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 7677-7687.	3.0	51
17	Production of Phosphatidylinositol 5-Phosphate by the Phosphoinositide 3-Phosphatase Myotubularin in Mammalian Cells. Journal of Biological Chemistry, 2004, 279, 7304-7312.	3.4	127
18	Expression of Myotubularin by an Adenoviral Vector Demonstrates Its Function as a Phosphatidylinositol 3-Phosphate [PtdIns(3)P] Phosphatase in Muscle Cell Lines: Involvement of PtdIns(3)P in Insulin-Stimulated Glucose Transport. Molecular Endocrinology, 2003, 17, 2448-2460.	3.7	75